Advertisement
Dr. Xie is a veteran in the biopharmaceutical industry and has publishedseveral papers and articles related to the field of plasma-based research. Heholds a number of patents related to his biopharmaceutical research, includingresearch on plasma-derived hyperimmune globulins and alpha-1 proteinaseinhibitor, and has received the Guangzhou City Science and Technology Award inconnection with his work "Preparation of Equine Antibodies against AvianInfluenza." Prior to joining China Biologic, Dr. Xie served from 2007 to 2009as the General Manager of Research and Development at New a-IKOR Limited, aHong Kong-based biopharmaceutical company, and from 2002 to 2007, as theDirector of Research & Development at Advantek Serum Laboratories Limited, aHong Kong plasma-based biopharmaceutical company. Dr. Xie has also conductedpostdoctoral research in various departments in the University of Hong Kongand the Chinese University of Hong Kong.
Advertisement
"We are very pleased to have Dr. Xie join our research team," commentedMr. Chao Ming Zhao, CEO of China Biologic Products. "He brings years ofresearch experience and managerial expertise related to the biopharmaceuticalindustry to China Biologic Products. We expect that his presence on our teamwill serve to strengthen our research and development efforts as part of ourstrategy to bring new higher margin products to market."
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirectmajority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. andChongqing Dalin Biologic Technologies Co., Ltd, and its equity investment inXi'an Huitian Blood Products Co., Ltd., is currently the largestnon-state-owned plasma-based biopharmaceutical company in China. The Companyis a fully integrated biologic products company with plasma collection,production and manufacturing, research and development, and commercialoperations. The Company's plasma-based biopharmaceutical products areirreplaceable during medical emergencies, and are used for the prevention andtreatment of various diseases. It sells its products to hospitals and otherhealthcare facilities in China.
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating tothe business of China Biologic Products, Inc. and its subsidiary companies.All statements, other than statements of historical fact included herein are"forward-looking statements," including statements regarding: the impact ofthe appointment of Mr. Xie as the Company's new Director of Research; theability of the Company to achieve its commercial objectives; the businessstrategy, plans and objectives of the Company and its subsidiaries, includingthe possibility that Mr. Xie's presence will advance the Company's strategy tobring new higher margin products to market; and any other statements ofnon-historical information. These forward-looking statements are oftenidentified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks anduncertainties. Although the Company believes that the expectations reflectedin these forward-looking statements are reasonable, they do involveassumptions, risks and uncertainties, and these expectations may prove to beincorrect. Investors should not place undue reliance on these forward-lookingstatements, which speak only as of the date of this press release. TheCompany's actual results could differ materially from those anticipated inthese forward-looking statements as a result of a variety of factors,including those discussed in the Company's periodic reports that are filedwith the Securities and Exchange Commission and available on its website( http://www.sec.gov ). All forward-looking statements attributable to theCompany or persons acting on its behalf are expressly qualified in theirentirety by these factors. Other than as required under the securities laws,the Company does not assume a duty to update these forward-looking statements.For more information, please contact: Company Contact: China Biologic Products, Inc. Mr. Y. Tristan Kuo Chief Financial Officer Tel: +86-538-6202206 Email: [email protected] Web: http://www.chinabiologic.com Investor Relations Contact: CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 (NY office) Email: [email protected] Mr. Gary Chin Tel: +1-646-213-1909 Web: http://www.ccgirasia.com
SOURCE China Biologic Products, Inc.
